Dec 11, 2024
top of page
JNJ: New Imaavy faces headwinds from Myasthenia incumbents but promising in other FcRn markets
May 21, 2025
The market continues to underestimate Imaavy's prospects from current and potential FcRn indications. While we see stiff barriers for Imvaay in Myasthenia Gravis despite recent FDA approval, leaving Vyvgart dominant, we see significant unopposed upside for Imvaay in other indications…
bottom of page